Boundless Bio, Inc.
NASDAQ:BOLDBiotechnology
+$1.20 today
- Market cap
- $56.67M
- Beta
- 0.97
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$2.50
Volume 0.15M
Average 0.22M
BOLD Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Boundless Bio, Inc.NASDAQ: BOLD
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash dips below year-ago levels
Q1 FY2026 net change in cash of $385K (cash outflow) fell 96.6% year over year, behind the +123.6% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -28.0% a year.
Context
- Net change in cash increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -96.6% toward the trailing-twelve-month pace of +123.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (8.72M) USD
- Year-over-year change
- -402.6%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.72M) | -402.6% |
| FY2024 | 2024-12-31 | 2.88M | -77.5% |
| FY2023 | 2023-12-31 | 12.78M | +154.8% |
| FY2022 | 2022-12-31 | (23.34M) | -201.5% |
| FY2021 | 2021-12-31 | 22.99M | — |
Net Change in Cash vs competitors
How BOLD compares with its peers on the latest reported figures
- BOLD's LTM Mar 2026 net change in cash of $2.37M is the smallest of the 4 companies compared; the peer median is $26.52M.
- Its year-over-year change of +123.6% is the 3rd highest of 4, against a peer median of +686.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.5M | +811.6% | — | — | |
| LTM Mar 2026 | $26.52M | +686.5% | — | 3090.9% | |
| LTM Mar 2026 | $14.73M | -70.6% | — | 27.4% | |
| LTM Mar 2026 | $2.37M | +123.6% | -28.0% | — | |
| Peer median (excluding BOLD) | $26.52M | +686.5% | — | 1559.2% | |
Competitors are the stored peer set for BOLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.21M) | (45.9M) | (49.43M) | (65.36M) | (58.2M) |
| Depreciation & Amortization | 682K | 942K | 957K | 1.09M | 1.25M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.16M | 2.29M | 3.34M | 7.52M | 6.13M |
| Change in Working Capital | (837K) | 866K | (799K) | (1.68M) | 3.46M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.91M | 0 | 775K | 1.63M |
| Other Working Capital | (837K) | (1.05M) | (799K) | (2.45M) | 1.83M |
| Other Non-Cash Items | 959K | 2.21M | (915K) | (2.4M) | 698K |
| Operating Cash Flow | (23.25M) | (39.6M) | (46.86M) | (60.84M) | (46.66M) |
| Capital Expenditures | (2.03M) | (1.07M) | (633K) | (2.54M) | (546K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (77.49M) | (42.6M) | (160.12M) | (208.47M) | (174.9M) |
| Sales of Investments | 20.24M | 59.8M | 122.5M | 184.9M | 213.24M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (59.29M) | 16.13M | (38.26M) | (26.1M) | 37.8M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 126K | 0 | 93M | 141K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 208K | 0 | (1.77M) | (3.18M) | 0 |
| Financing Cash Flow | 105.53M | 126K | 97.9M | 89.82M | 141K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 22.99M | (23.34M) | 12.78M | 2.88M | (8.72M) |
| Free Cash Flow | (25.28M) | (40.66M) | (47.49M) | (63.38M) | (47.21M) |
Boundless Bio, Inc.
NASDAQ:BOLD
Intrinsic Alpha fair value
Locked
Current Price
$2.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.